ClinicalTrials.gg
Active, not recruitingNCT04627428Updated Nov 13, 2026

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

A Phase 1/2 interventional study of RPESC-RPE-4W in Dry Age-related Macular Degeneration, sponsored by Luxa Biotechnology, LLC. Active, not recruiting at 3 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Luxa Biotechnology, LLC · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
400th of 491
18 · median 55
Started
2022
with 35 others
Phase 1/2
61 of 645
7 open now
Primary completion
2028-08
later than 93 of 124 live
Registered
458th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 400th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 61 in phase 1/2, reaches primary completion later than 93 of the 124 other live ones, and was the 458th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

Read the detailed description

RPESC-RPE-4W is Allogeneic RPE stem cell (RPESC)-derived RPE cells (RPESC-RPE) isolated from the RPE layer of human cadaveric eyes are transplanted under the macular.

This first-in-human Phase 1/2a open-label dose-escalation interventional study plans to enroll a total of 18 subjects

03

Conditions studied

  • Dry Age-related Macular Degeneration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of dry AMD.
  2. Ability to understand and give .
  3. Adult male or female >55 years of age.
  4. Medically suitable to undergo vitrectomy and subretinal injection (>60% on scale).
  5. if female (expected to be common for the age limitation), or the female partner of a male subject unable to father children.
  6. If male, willing to use barrier and spermicidal during the study.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or to dilation drops or fluorescein.
  2. Active major medical conditions limiting ability to participate in the study.
  3. Active or treatment with chemotherapy.
  4. Systemic therapy within past six months.
  5. History of toxoplasmosis, retinal histoplasmosis or tuberculosis.
  6. Receipt of product (IP) in a clinical trial within prior six months.
  7. Any other medical condition, which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromises subject safety, or interferes with the interpretation of the study results.
  8. Pregnant or nursing females.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    50,000 cells

    Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.

    Biological: RPESC-RPE-4W

  • Experimental
    150,000 cells

    Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.

    Biological: RPESC-RPE-4W

  • Experimental
    250,000 cells

    Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.

    Biological: RPESC-RPE-4W

Interventions

  • BiologicalRPESC-RPE-4W

    RPESC-RPE-4W

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of RPESC-RPE-4W transplantation

    The transplantation of RPESC-RPE-4W cells will be considered safe and tolerated in the absence of: * Decrease in visual acuity (VA) of more than 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (or to worse than counting fingers at three feet) from baseline * Any Grade 2 (CTCAE v5.0) or greater non-ocular Adverse Events (AE) related to the RPESC-RPE-4W investigational product (IP) or investigational interventions * Intraocular inflammation indicating contamination with an infectious agent or serious immune response greater than moderate severity related to the RPESC-RPE-4W investigational product or investigational interventions * Tumor formation \> 1 mm size related to the IP or investigational interventions

    Time frame: 24 months

Secondary outcomes

  1. Change in the mean of Best Corrected Visual Acuity (BCVA)

    Change in visual acuity will be measured by ETDRS chart.

    Time frame: 24 months

  2. Loss of ≥10 decibels of ten-degree average visual sensitivity microperimetry

    Loss of ≥10 decibels of ten-degree average visual sensitivity will by measured by microperimetry.

    Time frame: 24 months

  3. Change in GA lesion area

    Change in GA lesion area will be measured.

    Time frame: 24 months

  4. Evidence of structural changes

    Structural evidence will be measured by OCT imaging, autofluorescence, fluorescein angiography, and fundus photography

    Time frame: 24 months

07

Study locations

3 sites
08

References and documents

Publications

  • Rao RC, Arduini BL, Borden S, Sareen D, Svendsen C, Lee P, Ryan C, Kodati S, Nyaiburi C, Wolsieffer K, Oh E, Park S, Ford G, Dionne K, Temple S, Stern J. Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes. Cell Stem Cell. 2025 Nov 6;32(11):1659-1670.e4. doi: 10.1016/j.stem.2025.08.012. Epub 2025 Sep 16. PubMed 40961946 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Aug 2028, 76 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 76 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Aug 2028 and completion Dec 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2020
First posted
Nov 13, 2020
StartActual
Apr 5, 2022
Primary completionEst.
Aug 5, 2028was Dec 2026
CompletionEst.
Aug 5, 2028was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 13, 2026
Primary completion
Dec 1, 2026→Aug 5, 2028
Nov 13, 2026
Study completion
Dec 1, 2026→Aug 5, 2028
Nov 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40961946 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40961946 ↗
    Primary completion Dec 1, 2026→Aug 5, 2028
    Study completion Dec 1, 2026→Aug 5, 2028
    + 5 other changes: identifiers, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04627428
Lead sponsor
Luxa Biotechnology, LLC
Collaborators
National Institutes of Health (NIH), National Eye Institute (NEI), Regenerative Research Foundation, California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Nov 13, 2020
Start date
Apr 5, 2022
Primary completion
Aug 5, 2028 (estimated)
Completion
Aug 5, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Rajesh C Rao, M.D.
principal investigator · University of Michigan Kellogg Eye Center
Theodore Leng, MD, FACS
principal investigator · Spencer Center for Vision Research at Stanford University
David S Liao, MD, PhD
principal investigator · Retina-Vitreous Associates Medical Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion